{
  "model": "qwen/qwen3.6-35b-a3b",
  "started_at": "2026-06-05T21:02:11.279Z",
  "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft a\nhigh-conviction idea, draft a clearly labeled paper-tracked research idea,\nor skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes normal\nrecommendation-grade ideas rarely and only when something clears a high bar.\nMost dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": <num> }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\nPaper-tracked ideas are a separate measurement lane: they are zero-position,\nlow-confidence research setups used to learn whether the model's medium-grade\nsignals work over time. They must never read like a buy/sell recommendation.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n   • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n     last 90 days totaling ≥ $500K\n   • +3 pts if CEO is among the buyers\n   • +3 pts if CFO is among the buyers\n   • +2 pts if total purchases > $5M\n   • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n     Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n   • +3 pts if it's in the manager's top-3 positions\n   • 2 pts for politician STOCK Act recent buy\n   • +1 pt if multiple unrelated members bought within 30 days\n   • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n   • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n     and flow_strength ∈ {moderate, strong}\n   • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n   • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n   • 1 pt: large OI building at a defended price level\n   • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n     without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n   • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n   • 8 pts: pending product launch / FDA / contract milestone in horizon\n   • 5 pts: recent guidance raise (last 90 days)\n   • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n     to this name in $)\n   Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n   • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n     earnings)\n   • 4 pts: EV/EBITDA ≥ 30% below sector median\n   • 4 pts: FCF yield ≥ 7% with stable FCF\n   • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n   Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n   • 5 pts: ROIC ≥ 15% (or trending there)\n   • 5 pts: gross margin expanding ≥ 3pp YoY\n   • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n   • 3 pts: above both 50DMA and 200DMA\n   • 4 pts: 12-1 month price return positive AND beating sector\n   • 2 pts: RSI 14 in 40-65 zone\n   • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n   \"core\"        — market_cap > $5B. Standard methodology sizing.\n   \"asymmetric\"  — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n                   bets lose money or go to zero; the few that work pay\n                   for the rest. Position sizing is far more conservative\n                   to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n  CORE risk_class:\n   ≥ 80    Publish, confidence 5, position size cap 4-5%\n   70-79   Publish, confidence 4, position size cap 2.5-3.0%\n   60-69   Publish, confidence 3, position size cap 1.5-2.0%\n   45-59   Paper-track if no hard anti-signal and the thesis is specific,\n           measurable, and falsifiable; otherwise skip\n   < 45    Skip\n\n  ASYMMETRIC risk_class — strict sizing:\n   ≥ 80    Publish, confidence 5, position size cap 1.5%\n   70-79   Publish, confidence 4, position size cap 1.0%\n   60-69   Publish, confidence 3, position size cap 0.5%\n   45-59   Paper-track only if there is a concrete dated catalyst or\n           measurable event path; otherwise skip\n   < 45    Skip\n   Structure must be long_stock (options structures are wrong shape for\n   moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n   • Going-concern audit qualification\n   • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n   • Customer concentration > 30%\n   • Convertible/warrant overhang creating dilution > 10% of float\n   • Accounting irregularities (restatements, auditor changes)\n   • Avg daily volume < $5M (liquidity gate)\n   • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nPAPER-TRACKING LANE (educational measurement, not advice)\n\nUse this lane for score 45-59 dossiers that are not strong enough for a\nnormal publication but are specific enough to evaluate later. Requirements:\n   • draft.paper_track MUST be true\n   • headline MUST begin with \"Paper Track:\"\n   • thesis_short MUST explicitly say this is a paper-tracked research setup,\n     not an actionable recommendation\n   • risk.position_size_pct MUST be 0\n   • confidence MUST be 1 or 2 (2 only when score ≥55)\n   • exit.time_horizon_months MUST be present so Monitor can close it\n   • use long_stock unless the dossier gives complete, current option\n     contract data for the chosen income structure\n\nDo not paper-track dossiers with methodology anti-signals, stale numbers,\nmissing sources, unverified catalyst dates, or generic \"cheap/AI/tailwind\"\nstories. Skip those.\n\nUPSIDE TARGET\n\nThe desk is looking for setups with a plausible 20%+ return target. For\nlong_stock, exit.target_price should be at least 20% above entry.price_at_idea\nunless the idea is explicitly a paper-tracked post-event study. If the\nsource-backed upside is less than 20%, skip rather than publishing a low-upside\nidea.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n  verdict='promising'              → long_stock | csp (for asymmetric long)\n  verdict='range_bound_or_income'  → cc | strangle | csp on pullback\n                                     (DON'T default to long_stock — Scout\n                                      already said this isn't an asymmetric\n                                      long. Look at IV elevated → strangle;\n                                      stock at 52w high, fundamentals healthy\n                                      → cc against implicit long; pullback\n                                      thesis with cash → csp)\n  verdict='bearish_setup'          → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n   long_stock   — multi-quarter asymmetric thesis, IV not elevated, want\n                  full upside participation\n   csp          — bullish, want to own at strike, IV elevated, ann yield ≥15%\n   cc           — range-bound or mildly bullish, IV elevated, on top of long\n                  stock leg, if-called return ≥15% ann\n   strangle     — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n                  put. Need: comfortable owning at put_strike, no parabolic\n                  upside expectation. Ann yield ≥12%. Compute and emit\n                  breakeven_high (call_strike + total_premium) and\n                  breakeven_low (put_strike - total_premium).\n   naked_put    — same setup as CSP but using margin. ~2x yield, margin call\n                  risk. Only for margin-equipped accounts. Note explicitly.\n   naked_call   — bearish setup with elevated IV. UNCAPPED loss if rally.\n                  Confidence ceiling 4 (Compliance enforces). Requires\n                  explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n  {\n    \"skip\": true,\n    \"score\": <0-100 composite>,\n    \"score_breakdown\": {\n      \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n      \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n    },\n    \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n  }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n  \"skip\": false,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": {\n    \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n    \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n  },\n  \"draft\": {\n    \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n    \"paper_track\": false,\n    \"symbol\": \"TICKER\",\n    \"company\": \"Full name\",\n    \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n    \"risk_class\": \"core\" | \"asymmetric\",\n    \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n    \"thesis_short\": \"1 sentence — why this trade exists.\",\n    \"thesis_long\": [\n      \"Opening paragraph framing the setup.\",\n      \"## Catalyst\",\n      \"Detailed catalyst narrative.\",\n      \"## Why the market is mispricing this\",\n      \"Edge explanation, citing dossier facts.\",\n      \"## Numbers\",\n      \"- Bullet 1 with concrete numbers from the dossier\",\n      \"- Bullet 2\",\n      \"## Risk\",\n      \"Honest description of what could go wrong.\"\n    ],\n    \"structure\": {\n      \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n      \"long_stock\":   { \"entry_zone_low\": <num>, \"entry_zone_high\": <num>, \"shares_per_unit\": 100 },\n      \"csp\":          { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"if_assigned_basis\": <num> },\n      \"cc\":           { \"underlying_basis\": <num>, \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"if_called_return_pct\": <num> },\n      \"strangle\":     { \"call_strike\": <num>, \"put_strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": <num>, \"put_premium_target\": <num>, \"total_premium_target\": <num>, \"breakeven_high\": <num>, \"breakeven_low\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_note\": \"...\" },\n      \"naked_put\":    { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_per_contract\": <num>, \"margin_estimate_per_contract\": <num>, \"warning\": \"...\" },\n      \"naked_call\":   { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n    },\n    \"entry\": {\n      \"price_at_idea\": <last_close from dossier>,\n      \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n    },\n    \"exit\": {\n      \"target_price\": <num or null for options structures>,\n      \"time_horizon_months\": <int 3-12>,\n      \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n    },\n    \"risk\": {\n      \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n      \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n      \"position_size_pct\": <0.0 for paper_track, otherwise 0.5 to 5.0 conviction-weighted>\n    },\n    \"sources\": [\n      { \"label\": \"...\", \"url\": \"...\" }\n    ],\n    \"confidence\": <1-5, conservative>,\n    \"analyst\": \"research-desk\",\n    \"scout_model\": \"minimax/minimax-m2.7\",\n    \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n    \"devils_advocate_verdict\": null\n  }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.",
  "user_prompt": "CURRENT DATE: 2026-06-05. THE YEAR IS 2026.\nDATE RULES — read before writing ANY date:\n  - Every option expiry, earnings date, catalyst date, and DTE you state MUST use the year 2026 or later. Do NOT write 2025 dates — your training prior is stale.\n  - Every option expiry MUST be a real FUTURE date relative to 2026-06-05. Copy expiries verbatim from options_expiries()/the dossier — never infer a year from memory.\n  - Before writing a date, check it: if it is earlier than 2026-06-05, it is WRONG — re-read the live tool output.\n\nHere is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n  \"symbol\": \"SGHT\",\n  \"company\": \"Sight Sciences, Inc.\",\n  \"investigation_summary\": \"Sight Sciences makes ophthalmic surgical devices for glaucoma (OMNI Surgical System) and dry eye disease (TearCare). The investigation trigger — 3 Form 4 filings in 14 days — was met (June 4-5, 2026), but all three were director RSU grants under the Non-Employee Director Compensation Program at $0.00 price, NOT open-market purchases. This is a critical distinction: the smart-money signal is noise. However, two genuinely material catalysts exist: (1) A March 27, 2026 Delaware federal court ruling preserving a jury verdict of willful patent infringement against Alcon's Hydrus Microstent and awarding $34M in damages plus an ongoing 10% royalty through November 2028 — potentially worth hundreds of millions if collected. (2) Q1 FY26 earnings beat on May 6, 2026 with revenue guidance raised for full-year 2026. The company is deeply unprofitable (forward P/E N/M), burning $7-13M cash per quarter, and the stock trades ~52% below its 52-week high of $9.05. Valuation at current prices reflects substantial skepticism about execution; if the Alcon damages are ultimately collected without reversal on appeal, SGHT's financial trajectory transforms materially.\",\n  \"verdict\": \"range_bound_or_income\",\n  \"confidence_in_data\": 4,\n  \"structure_hints\": [\n    \"csp\",\n    \"strangle\"\n  ],\n  \"business_snapshot\": \"Sight Sciences operates two segments: Interventional Glaucoma (OMNI Surgical System and SION device for MIGS procedures treating primary open-angle glaucoma) and Interventional Dry Eye (TearCare system for meibomian gland dysfunction). The company estimates its total U.S. addressable market at ~$6B in glaucoma plus $2.4B in dry eye treatments. OMNI is covered by all Medicare Administrative Contractor jurisdictions and numerous private insurers, providing a commercial foundation. Q1 FY26 revenue was $19.7M (+12.5% YoY), with gross margins of 86%. The company raised full-year 2026 revenue guidance above prior estimates while maintaining adjusted operating expense guidance, signaling improving operational leverage. Cash burn narrowed to $7M in Q1 from $11.6M a year ago; cash balance was ~$85M at March 31, 2026.\",\n  \"scoring_inputs\": {\n    \"smart_money\": {\n      \"insider_open_market_purchases_90d\": [],\n      \"insider_open_market_total_usd_90d\": 0,\n      \"distinct_insider_buyers_90d\": 0,\n      \"ceo_buy_present\": false,\n      \"cfo_buy_present\": false,\n      \"material_insider_selling_90d_usd\": null,\n      \"notable_13f_holders\": [\n        \"pending — v2\"\n      ],\n      \"politician_recent_buys\": [\n        \"pending — v2\"\n      ]\n    },\n    \"catalyst\": {\n      \"next_earnings_date\": \"2026-08-06\",\n      \"recent_eps_surprise_pattern\": \"Q1 FY26 beat: EPS -$0.24 vs estimate -$0.20 (missed), revenue $19.7M vs estimate $18.6M (+6% beat). Prior 3 quarters all positive surprises on both EPS and revenue.\",\n      \"guidance_raise_in_last_90d\": true,\n      \"named_catalysts\": [\n        {\n          \"type\": \"regulatory/legal\",\n          \"description\": \"March 27, 2026 Delaware District Court order preserving jury verdict of willful patent infringement by Alcon's Hydrus Microstent; $34M damages awarded plus ongoing 10% royalty on Hydrus revenues through November 10, 2028 (patent expiration). Final judgment pending. Subject to appeal and USPTO ex parte reexamination.\",\n          \"date_or_window\": \"Judgment expected coming months; appeals could take 2+ years\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1531177/000119312526130386/sght-20260327.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"earnings\",\n          \"description\": \"Q1 FY26 beat with revenue +12.5% YoY and full-year 2026 guidance raised; next earnings August 6, 2026.\",\n          \"date_or_window\": \"2026-08-06\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/sight-sciences-reports-first-quarter-200500618.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"product/clinical\",\n          \"description\": \"ASCRS Annual Meeting April 2026: clinical presentations on OMNI and TearCare; potential positive data catalysts.\",\n          \"date_or_window\": \"April 2026\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/sight-sciences-interventional-technologies-glaucoma-200500321.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        }\n      ]\n    },\n    \"mispricing\": {\n      \"forward_pe\": null,\n      \"sector_median_forward_pe\": null,\n      \"ev_to_ebitda\": -7.67,\n      \"sector_median_ev_to_ebitda\": null,\n      \"fcf_yield_pct\": 3.54,\n      \"sotp_gap_pct\": null,\n      \"narrative\": \"At ~$4.45, SGHT trades at a steep discount to its 52-week high of $9.05 (down ~52%). The stock appears to fully price in the risk that Alcon's appeals succeed and the patent damages are reversed, and further prices in skepticism about the company's path to profitability given ongoing losses. If the $34M + royalty stream ultimately materializes without reversal, the implied value is substantially above current market cap of ~$242M.\"\n    },\n    \"quality\": {\n      \"roic_pct\": null,\n      \"gross_margin_trend_pp_yoy\": \"86% gross margin stable; up modestly from prior year\",\n      \"net_debt_to_ebitda\": null,\n      \"balance_sheet_grade\": \"B\"\n    },\n    \"technical\": {\n      \"above_50dma\": true,\n      \"above_200dma\": false,\n      \"rsi_14\": 45.7,\n      \"macd_recent_bullish_cross\": false,\n      \"12_1_momentum_vs_sector_pct\": null\n    }\n  },\n  \"price_context\": {\n    \"last_close\": 4.45,\n    \"ytd_return_pct\": 5.95,\n    \"from_52w_high_pct\": 51.8\n  },\n  \"filings_reviewed\": [\n    {\n      \"form\": \"10-K\",\n      \"filed\": \"2026-03-04\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1531177/000119312526091558/sght-20251231.htm\",\n      \"key_takeaways\": [\n        \"FY2025 annual report for year ended December 31, 2025; $79.6M TTM revenue at filing date (+12.5% YoY); gross margin 86%; accumulated deficit $397.7M; cash $84.9M as of March 31, 2026 per Q1 10-Q; Hercules Capital credit facility with ~$41M drawn and covenants to monitor\"\n      ]\n    },\n    {\n      \"form\": \"10-Q\",\n      \"filed\": \"2026-05-06\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1531177/000119312526209116/sght-20260331.htm\",\n      \"key_takeaways\": [\n        \"Q1 FY26: revenue $19.7M (+12.5% YoY), gross margin 86%, net loss $(13.0)M; operating expenses $29.4M (SG&A-heavy); cash burn $7M in quarter vs $11.6M year-ago; guidance raised for full-year FY2026\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-03-30\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1531177/000119312526130386/sght-20260327.htm\",\n      \"key_takeaways\": [\n        \"March 27, 2026 court order: $34M damages against Alcon + ongoing 10% royalty on Hydrus revenues through Nov 2028; willful infringement verdict preserved by jury\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-06-05\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1531177/000119312526259546/sght-20260604.htm\",\n      \"key_takeaways\": [\n        \"Annual stockholders meeting June 4, 2026: director elections (Gerhard Burbach and Staffan Encrantz re-elected); auditor ratified\"\n      ]\n    },\n    {\n      \"form\": \"10-Q\",\n      \"filed\": \"2025-11-06\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1531177/000119312525269613/sght-20250930.htm\",\n      \"key_takeaways\": [\n        \"Q3 FY25: revenue $19.6M (+9% YoY), net loss $(4.5)M; consecutive positive EPS surprise quarters\"\n      ]\n    }\n  ],\n  \"options_context\": {\n    \"expiries_examined\": [\n      \"2026-06-18\",\n      \"2026-07-17\",\n      \"2026-08-21\",\n      \"2026-11-20\"\n    ],\n    \"iv_summary\": \"August 21, 2026 expiry: ATM IV data sparse — single call strike (5.0) shows IV of ~113%; limited OI and volume; options market very thin for this small-cap medtech name.\",\n    \"notable_skew_or_flow\": \"Options flow tool returned neutral/weak signal with near-zero activity in current feed. No whale blocks detected in available data.\"\n  },\n  \"competitive_landscape\": \"SGHT competes in MIGS (microinvasive glaucoma surgery) against Alcon's Hydrus Microstent, Glaukos iStent franchise, Allergan/AbbVie's XEN gel stent, and New World Medical's Ahmed device. In dry eye/TearCare: competes with TearScience (acquired by Johnson & Johnson), Niui Surgical, and various pharmaceutical approaches (Restasis, Xiidra, Cequa). The Alcon patent litigation win is directly relevant to competitive moat — a favorable outcome strengthens SGHT's IP position against its primary MIGS rival.\",\n  \"key_risks\": [\n    \"Alcon appeal reversal risk: ex parte USPTO reexamination of asserted patents could result in claim invalidation if upheld on Federal Circuit appeal\",\n    \"Continued operating losses and cash burn ($7-13M/quarter); company may need additional capital raises (dilutive)\",\n    \"Single-product concentration risk within each segment; OMNI is the primary revenue driver\",\n    \"Reimbursement risk for TearCare commercial coverage remains incomplete vs. OMNI which has Medicare MAC coverage in all jurisdictions\",\n    \"Illiquidity of options chain makes income strategies difficult to execute at fair mid\",\n    \"Stock down ~52% from 52-week high — technical damage indicates sustained institutional disinterest\"\n  ],\n  \"what_the_market_might_be_missing\": \"The Alcon patent verdict ($34M cash + ongoing 10% Hydrus royalty through November 2028) is potentially worth $150-300M+ in total value depending on Hydrus revenue trajectory. If this judgment stands post-appeal, it fundamentally changes SGHT's balance sheet and could accelerate the path to profitability (reducing need for dilutive financing). The market may be discounting this too heavily given appeal uncertainty, treating the stock as a loss-making small-cap with no special catalyst rather than a company holding a potentially transformative IP monetization event. However, timing of collection is highly uncertain due to multi-year appellate process.\",\n  \"anti_signals_present\": [\n    \"going_concern\",\n    \"dilution\",\n    \"accounting\"\n  ],\n  \"sources\": [\n    {\n      \"label\": \"Q1 FY26 10-Q (March 31, 2026)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1531177/000119312526209116/sght-20260331.htm\"\n    },\n    {\n      \"label\": \"FY2025 10-K (December 31, 2025 filed March 4, 2026)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1531177/000119312526091558/sght-20251231.htm\"\n    },\n    {\n      \"label\": \"8-K — Alcon Patent Verdict Preservation (March 27, 2026 order)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1531177/000119312526130386/sght-20260327.htm\"\n    },\n    {\n      \"label\": \"Form 4 — Director Gerhard Burbach RSU grant June 4, 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1531177/000119312526259565/xslF345X06/ownership.xml\"\n    },\n    {\n      \"label\": \"Form 4 — Director Donald Zurbay RSU grant June 4, 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1531177/000119312526259558/xslF345X06/ownership.xml\"\n    },\n    {\n      \"label\": \"Q1 FY26 Earnings Release (May 6, 2026)\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/sight-sciences-reports-first-quarter-200500618.html\"\n    }\n  ],\n  \"unfetched_signals\": [\n    \"13f_deltas\",\n    \"politician_trades\",\n    \"sentiment_score\"\n  ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude <think>...</think> reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.",
  "completions": [
    {
      "ts": "2026-06-05T21:02:45.673Z",
      "raw_content": "<think>The user wants me to act as the \"Analyst\" in a trade-ideas pipeline.\nI need to score the provided dossier based on a specific rubric and decide whether to skip, paper-track, or publish a high-conviction idea.\n\nLet's evaluate the dossier for SGHT (Sight Sciences, Inc.).\n\n**Scoring Inputs:**\n- **Smart Money (A):** Insider open market purchases 90d: 0. CEO/CFO buy: false. 13F holders: pending. Politician buys: pending. -> Score: 0.\n- **Options Flow / UOA (B):** IV summary: ATM IV sparse, call strike 5.0 shows IV ~113%. Notable skew/flow: neutral/weak, near-zero activity. No whale blocks. -> Score: 0. (Maybe 1 pt for high IV? But flow is neutral. Let's give 0 or 1. I'll stick to 0 for lack of flow.)\n- **Catalyst (C):** Next earnings: 2026-08-06. Recent EPS surprise: Q1 missed EPS but beat revenue. Prior 3 quarters positive. Not >0% for last 4. So 0 pts for that. Guidance raise in last 90d: true. (+5 pts). Named catalysts: Alcon patent verdict ($34M + 10% royalty). This is a legal/regulatory catalyst. (+8 pts for pending product launch/FDA/contract milestone? It's a legal milestone. Let's give 5 pts for legal/regulatory milestone). Total Catalyst: ~10 pts. (Cap is 25). Let's say 10.\n- **Mispricing (D):** Forward P/E: null (unprofitable). EV/EBITDA: -7.67. FCF yield: 3.54%. SOTP gap: null. Narrative says stock trades at steep discount to 52w high, but fully prices in appeal risk. No clear quantitative mispricing per rubric (P/E, EV/EBITDA, FCF yield don't hit thresholds). -> Score: 0.\n- **Quality (E):** ROIC: null. Gross margin trend: 86% stable. Net debt/EBITDA: null. Balance sheet grade B. -> Score: 0. (Gross margin stable, not expanding ≥3pp YoY).\n- **Momentum/Technical (F):** Above 50DMA: true (+3). Above 200DMA: false. RSI 14: 45.7 (+2 pts). MACD: false. 12-1 momentum: null. -> Score: 5.\n\nTotal Score: ~15.\n\n**Risk Class:** Market cap ~$242M. -> \"asymmetric\".\n\n**Anti-Signal Gates:**\n- `anti_signals_present`: [\"going_concern\", \"dilution\", \"accounting\"]\n- The prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\n- Going concern audit qualification: The dossier says \"going_concern\" in anti_signals. Usually implies material doubt about ability to continue.\n- Dilution: \"Continued operating losses... may need additional capital raises\".\n- Accounting: Listed in anti_signals.\nGiven the explicit anti-signals (going_concern, dilution, accounting) and the lack of strong smart money/flow/catalyst/quality/mispricing scores, this firmly falls into the SKIP category.\nAlso, the edge check: \"What does this idea say that the market doesn't already know?\" The market knows about the Alcon verdict but is discounting it due to appeal risk and burn. The edge is weak. The prompt says to skip if generic or weak.\n\n**Decision:** Skip.\n**Reason:** Anti-signal gates (going concern, dilution risk, accounting flags) are triggered, and the dossier lacks the smart money, flow, or quantifiable mispricing required to override the material execution and appellate risks.\n**Score:** ~15.\n\nLet's compute scores carefully to match rubric maxes.\nA: 0\nB: 0 (IV is high but flow is neutral/weak, no whale blocks)\nC: 10 (5 for guidance raise, 5 for legal milestone)\nD: 0\nE: 0\nF: 5 (3 for 50DMA, 2 for RSI)\nTotal: 15.\n\nWait, let's check rubric for C: \"8 pts: pending product launch / FDA / contract milestone in horizon\". Legal verdict might not fit perfectly, but I'll give 5 for guidance raise. Total C = 5 or 10. Let's stick with 10.\nTotal score ~15.\nRisk class: asymmetric.\nThresholds for asymmetric: <45 Skip.\nAnti-signals present: going_concern, dilution, accounting.\nI will output the skip JSON.\n\nStructure of skip JSON:\n{\n  \"skip\": true,\n  \"score\": 15,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 10,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 5\n  },\n  \"reason\": \"Triggered anti-signal gates for going concern, dilution, and accounting flags. The dossier lacks smart-money accumulation, sustained options flow, or quantifiable mispricing to offset the high appellate risk and ongoing cash burn.\"\n}\n\nDouble check the prompt: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nI can't articulate why they don't apply. So skip is mandatory.\nAll numbers and dates are consistent.\nOutput matches required format.\nProceed. \nOne minor point: The prompt says \"ONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that sub-object.\" This applies to the PROCEED case. For skip, it's just the skip block.\nI will generate the skip block.\nCheck score breakdown sum: 0+0+10+0+0+5 = 15. Correct.\nCheck risk class: market_cap ~$242M -> asymmetric.\nCheck thresholds: <45 Skip.\nAll good.\nOutput matches exactly. \nProceed. \nGenerating response. \n(Self-Correction/Refinement during thought)\nWait, let's look at the catalyst score again. \"5 pts: recent guidance raise (last 90 days)\" -> +5.\n\"8 pts: pending product launch / FDA / contract milestone in horizon\" -> The Alcon verdict is a legal milestone, not product/FDA. I'll give it 0 for that specific line, or maybe 5 for \"legal/regulatory milestone\" loosely, but rubric says 8 for product/FDA/contract. I'll stick to 5 for guidance raise. Total C = 5.\nTechnical: 3 pts for above 50DMA, 2 pts for RSI 40-65. Total F = 5.\nTotal = 10.\nI'll adjust score to 10.\nReason remains the same.\nOutput matches.\nDone. \nLet's produce the JSON. \nNote: I will ensure the JSON is valid and strictly follows the schema.\n```json\n{\n  \"skip\": true,\n  \"score\": 10,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 5,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 5\n  },\n  \"reason\": \"Triggered anti-signal gates for going concern, dilution, and accounting flags. The dossier lacks smart-money accumulation, sustained options flow, or quantifiable mispricing to offset the high appellate risk and ongoing cash burn.\"\n}\n```\nMatches requirements. Proceeds. \nOne detail: `scout_verdict` is `range_bound_or_income`. The prompt says \"Even when Scout says 'no asymmetric long opportunity exists' (verdict=range_bound_or_income), there may be a clear INCOME structure... Don't reflex-skip just because long_stock isn't attractive.\"\nHowever, the anti-signal gates are strict: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nGiven `going_concern`, `dilution`, and `accounting` are explicitly listed, and the company is burning cash with a pending appeal on its main asset, it's unsafe to draft even an income structure. The skip is justified.\nI will output the skip JSON. \nAll good. \nOutput matches. \nProceeds. \n[Final Check of the Prompt]\n\"ONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that sub-object. Leave the others null/omitted.\" -> Applies to PROCEED.\n\"IF YOU SKIP — output exactly: { ... }\" -> Applies here.\nReady. \nOutput Generation. \n(Self-Correction/Note during generation prep)\nI should make sure the score breakdown sums to the composite score. 0+0+5+0+0+5 = 10. Correct.\nThe reason explicitly addresses the anti-signals and lack of edge.\nAll constraints met.\nProceeds. \n[Output Generation] -> *Proceeds*\n</think>\n\n{\n  \"skip\": true,\n  \"score\": 10,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 5,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 5\n  },\n  \"reason\": \"Triggered anti-signal gates for going concern, dilution, and accounting flags. The dossier lacks smart-money accumulation, sustained options flow, or quantifiable mispricing to offset the high appellate risk and ongoing cash burn.\"\n}",
      "cleaned_content": "{\n  \"skip\": true,\n  \"score\": 10,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 5,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 5\n  },\n  \"reason\": \"Triggered anti-signal gates for going concern, dilution, and accounting flags. The dossier lacks smart-money accumulation, sustained options flow, or quantifiable mispricing to offset the high appellate risk and ongoing cash burn.\"\n}",
      "tool_calls": null,
      "finish_reason": "stop"
    }
  ],
  "tool_results": [],
  "final_message": "{\n  \"skip\": true,\n  \"score\": 10,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 5,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 5\n  },\n  \"reason\": \"Triggered anti-signal gates for going concern, dilution, and accounting flags. The dossier lacks smart-money accumulation, sustained options flow, or quantifiable mispricing to offset the high appellate risk and ongoing cash burn.\"\n}",
  "tool_calls_total": 0,
  "walltime_ms": 34394,
  "stop_reason": "stop",
  "completed_at": "2026-06-05T21:02:45.673Z"
}